Unknown

Dataset Information

0

Discovery of a potent thiadiazole class of histamine h3 receptor antagonist for the treatment of diabetes.

ABSTRACT: A series of novel 2-piperidinopiperidine thiadiazoles were synthesized and evaluated as new leads of histamine H3 receptor antagonists. The 4-(5-([1,4'-bipiperidin]-1'-yl)-1,3,4-thiadiazol-2-yl)-2-(pyridin-2-yl)morpholine (5u) displayed excellent potency and ex vivo receptor occupancy. Compound 5u was also evaluated in vivo for antidiabetic efficacy in STZ diet-induced obesity type 2 diabetic mice for 2 or 12 days. Non-fasting glucose levels were significantly reduced as compared with vehicle-treated mice. In addition, 5u dose dependently blocked the increase of HbA1c after 12 days of treatment.

SUBMITTER: Rao AU 

PROVIDER: S-EPMC4025655 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

A series of novel 2-piperidinopiperidine thiadiazoles were synthesized and evaluated as new leads of histamine H3 receptor antagonists. The 4-(5-([1,4'-bipiperidin]-1'-yl)-1,3,4-thiadiazol-2-yl)-2-(pyridin-2-yl)morpholine (5u) displayed excellent potency and ex vivo receptor occupancy. Compound 5u was also evaluated in vivo for antidiabetic efficacy in STZ diet-induced obesity type 2 diabetic mice for 2 or 12 days. Non-fasting glucose levels were significantly reduced as compared with vehicle-tr  ...[more]

Similar Datasets

Unknown SAR110894, a potent histamine H3-receptor antagonist, displays disease-modifying activity in a transgenic mouse model of tauopathy.
| S-EPMC5651361 | biostudies-literature
Unknown Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus.
| S-EPMC1560086 | biostudies-literature
Unknown Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B.
| S-EPMC5233962 | biostudies-literature
Unknown Discovery of a First-in-Class Potent Small Molecule Antagonist against the Adrenomedullin-2 Receptor.
| S-EPMC7432679 | biostudies-literature
Unknown Histamine H3 Receptor Antagonist Prevents Memory Deficits and Synaptic Plasticity Disruption Following Isoflurane Exposure.
| S-EPMC6492665 | biostudies-literature
Unknown The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes.
| S-EPMC4025728 | biostudies-literature
Unknown Discovery of MK-8318, a Potent and Selective CRTh2 Receptor Antagonist for the Treatment of Asthma.
| S-EPMC6047040 | biostudies-literature
Unknown Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma.
| S-EPMC5430394 | biostudies-literature
Unknown Covalent Inhibition of the Histamine H3 Receptor.
| S-EPMC6943558 | biostudies-literature
Unknown Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist.
| S-EPMC4007836 | biostudies-other